CN110678549A - 一种激活p21基因表达的方法 - Google Patents

一种激活p21基因表达的方法 Download PDF

Info

Publication number
CN110678549A
CN110678549A CN201980002538.7A CN201980002538A CN110678549A CN 110678549 A CN110678549 A CN 110678549A CN 201980002538 A CN201980002538 A CN 201980002538A CN 110678549 A CN110678549 A CN 110678549A
Authority
CN
China
Prior art keywords
nucleic acid
rag
gene
activating rna
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980002538.7A
Other languages
English (en)
Other versions
CN110678549B (zh
Inventor
李龙承
姜武林
吴建成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaiji Pharmaceutical Technology (Suzhou) Co.,Ltd.
Original Assignee
Sino-American Ruikang Nucleic Acid Technology (nantong) Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sino-American Ruikang Nucleic Acid Technology (nantong) Research Institute Co Ltd filed Critical Sino-American Ruikang Nucleic Acid Technology (nantong) Research Institute Co Ltd
Priority to CN202110841287.0A priority Critical patent/CN113584027A/zh
Publication of CN110678549A publication Critical patent/CN110678549A/zh
Application granted granted Critical
Publication of CN110678549B publication Critical patent/CN110678549B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了一种由正义寡核苷酸链和反义寡核苷酸链组成的激活或上调人p21基因表达的小激活RNA，其所述正义核酸链或反义核酸链与人p21基因启动子靶基因序列中的任一长度为16‑35个核苷酸的连续片段具有75％以上的同源性，其中人p21基因的靶序列选自由SEQ ID NO：5、6、7、8、9、10、11、12所示的序列组成的组。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980002538.7A 2018-04-10 2019-04-10 一种激活p21基因表达的方法 Active CN110678549B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110841287.0A CN113584027A (zh) 2018-04-10 2019-04-10 一种激活p21基因表达的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810316672 2018-04-10
CN2018103166721 2018-04-10
PCT/CN2019/082126 WO2019196883A1 (zh) 2018-04-10 2019-04-10 一种激活p21基因表达的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110841287.0A Division CN113584027A (zh) 2018-04-10 2019-04-10 一种激活p21基因表达的方法

Publications (2)

Publication Number Publication Date
CN110678549A true CN110678549A (zh) 2020-01-10
CN110678549B CN110678549B (zh) 2021-06-22

Family

ID=68163046

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980002538.7A Active CN110678549B (zh) 2018-04-10 2019-04-10 一种激活p21基因表达的方法
CN202110841287.0A Pending CN113584027A (zh) 2018-04-10 2019-04-10 一种激活p21基因表达的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110841287.0A Pending CN113584027A (zh) 2018-04-10 2019-04-10 一种激活p21基因表达的方法

Country Status (6)

Country Link
US (1) US20210024915A1 (zh)
EP (1) EP3778893A4 (zh)
JP (1) JP2021520220A (zh)
KR (1) KR20200143428A (zh)
CN (2) CN110678549B (zh)
WO (1) WO2019196883A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166814A1 (zh) * 2021-02-07 2022-08-11 中美瑞康核酸技术(南通)研究院有限公司 一种化学修饰的小激活rna
JP2024506883A (ja) * 2021-02-07 2024-02-15 ラクティゲン セラピューティクス 増殖硝子体網膜症を治療するための二重鎖核酸分子及びその使用
CN117377764A (zh) * 2021-02-08 2024-01-09 中美瑞康核酸技术(南通)研究院有限公司 多价寡核苷酸试剂及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150126578A1 (en) * 2010-04-28 2015-05-07 The Regents Of The University Of California Modified Small Activating RNA Molecules and Methods of Use
CN106032532A (zh) * 2015-03-17 2016-10-19 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604532C (en) * 2005-04-15 2017-03-07 The Regents Of The University Of California Small activating rna molecules and methods of use
CN102641508A (zh) * 2012-05-01 2012-08-22 浙江大学 靶向上调par-4基因小rna在制备抗膀胱癌药物中的应用
CN102657878B (zh) * 2012-05-01 2014-04-16 浙江大学 Ints6基因小激活rna在制备抗前列腺癌药物中的应用
WO2016145608A1 (zh) * 2015-03-17 2016-09-22 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用
CN107980001B (zh) * 2015-07-02 2021-12-17 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150126578A1 (en) * 2010-04-28 2015-05-07 The Regents Of The University Of California Modified Small Activating RNA Molecules and Methods of Use
CN106032532A (zh) * 2015-03-17 2016-10-19 中国医学科学院北京协和医院 一种小激活rna及其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOSAKA M.等: "Targeted p21(WAF1/DIP1) activation by RNAa inhibits hepatocellular", 《NUCLEIC ACID THERAPEUTICS》 *
李占婷等: "运用saRNA激活p21基因表达上调对肺癌细胞生长及化疗敏感性的影响", 《现代肿瘤医学》 *
李立廷: "结直肠癌中microRNA-150的表达与p21、p27的关系及其对细胞增殖的影响", 《中国学位论文全文数据库》 *
龚化等: "p21基因的saRNA表达质粒的构建及功能研究", 《现代泌尿生殖肿瘤杂志》 *

Also Published As

Publication number Publication date
WO2019196883A1 (zh) 2019-10-17
CN113584027A (zh) 2021-11-02
KR20200143428A (ko) 2020-12-23
CN110678549B (zh) 2021-06-22
EP3778893A4 (en) 2022-04-20
JP2021520220A (ja) 2021-08-19
US20210024915A1 (en) 2021-01-28
EP3778893A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
JP7432521B2 (ja) 新規小分子活性化ｒｎａ
CN110678549B (zh) 一种激活p21基因表达的方法
WO2006126040A1 (en) Bacterial and bacterial associated mirnas and uses thereof
JP2006528482A (ja) 核酸の逆転写及び／または増幅方法
US9809847B2 (en) Methods and compositions for detecting polynucleotides and fragments thereof
CA2785727A1 (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
Hoch et al. Bacillus subtilis 6S-2 RNA serves as a template for short transcripts in vivo
US10196662B2 (en) Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
US20070167388A1 (en) Nucleotide sequences promoting the trans-membrane transport of nucleic acids
WO2010103522A1 (en) Method for detection of nucleic acid sequences
EP3964582A1 (en) Oligomeric nucleic acid molecule, and application thereof in acute intermittent porphyria treatment
Ringuette et al. Stimulation of transcription of chromatin by specific small nuclear RNAs
Nenoi et al. Novel structure of a Chinese hamster polyubiquitin gene
KR101874089B1 (ko) 알앤에이 검출용 키트 및 방법
EP4166668A1 (en) Nucleic acid molecule targeting mitf gene and use thereof
CN113444807B (zh) 一种绵羊脂肪相关的circRNA及其应用
KR101873327B1 (ko) 애기 장대에서 유래한 신규 호밍 엔도뉴클레아제
Piacenti Tackling neuroblastoma: Development of PNA-based miR-34a mimics
Henry et al. A hybridization and enzyme blocking method to enrich minor cDNA sequences

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016997

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220608

Address after: Unit e595, floor 5, Lecheng Plaza, phase II, biomedical industrial park, 218 Sangtian street, Suzhou area, 215000 China (Jiangsu) pilot Free Trade Zone

Patentee after: Kaiji Pharmaceutical Technology (Suzhou) Co.,Ltd.

Address before: 226400 building 18, life and Health Industrial Park, Rudong high tech Zone, 888 Zhujiang Road, juegang street, Rudong County, Nantong City, Jiangsu Province

Patentee before: Sino-American Ruikang Nucleic Acid Technology (Nantong) Research Institute Co.,Ltd.